Skip to main content

Advertisement

SpringerLink
Log in

Advances Toward Precision Medicine in Juvenile Dermatomyositis

  • Pediatric Rheumatology (S Ozen, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We seek to provide a summary of the recent advances in juvenile dermatomyositis (JDM) that are moving the field toward precision care and personalized medicine for this uncommon condition.

Recent Findings

There has been a recent international focus on developing uniform classification, disease monitoring, and treatment for juvenile dermatomyositis. In addition, there has been a steady development of translational studies to determine the genetic determinants, transcriptomic profiles, and immune cell phenotypes in JDM.

Summary

Recent work toward standardization of disease classification, monitoring, and assessments together with advances in science, technology, and computing will facilitate the advancement toward true precision and personalized medicine in juvenile dermatomyositis in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016. https://doi.org/10.1111/joim.12444.

    Article  CAS  Google Scholar 

  2. Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr. 2018;195:16–27. https://doi.org/10.1016/j.jpeds.2017.12.053.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Huber AM, Mamyrova G, Lachenbruch PA, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2014;66(5):732–40. https://doi.org/10.1002/acr.22212.

    Article  Google Scholar 

  4. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012. https://doi.org/10.3109/03009742.2011.608376.

    Article  Google Scholar 

  5. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–43. https://doi.org/10.1097/MD.0b013e31829d08f9.

    Article  CAS  Google Scholar 

  6. Okong’o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J. 2016;14(1):60. https://doi.org/10.1186/s12969-016-0118-0.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tsaltskan V, Aldous A, Serafi S, et al. Long-term outcomes in Juvenile Myositis patients. Semin Arthritis Rheum. June 2019. https://doi.org/10.1016/j.semarthrit.2019.06.014.

  8. Mamyrova G, Rider LG, Ehrlich A, et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology (Oxford). 2017;56(8):1342–7. https://doi.org/10.1093/rheumatology/kex162.

    Article  Google Scholar 

  9. Habers GEA, Huber AM, Mamyrova G, et al. Brief report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheum. 2016;68(3):761–8. https://doi.org/10.1002/art.39466.

    Article  CAS  Google Scholar 

  10. Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol. 2018;16(1):84. https://doi.org/10.1186/s12969-018-0299-9.

    Article  Google Scholar 

  11. Phillippi K, Hoeltzel M, Byun Robinson A, et al. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr. 2017;184:38–44. https://doi.org/10.1016/j.jpeds.2017.01.046.

    Article  Google Scholar 

  12. Neely J, Long CS, Sturrock H, Kim S. The association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis. Arthritis Care Res. 2019. https://doi.org/10.1002/acr.23840.

    Article  Google Scholar 

  13. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(8):403–7. https://doi.org/10.1056/NEJM197502202920807.

    Article  CAS  PubMed  Google Scholar 

  14. •• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–64. https://doi.org/10.1136/annrheumdis-2017-211468. This article outlines new classification criteria for idiopathic inflammatory myopathies, including JDM, replacing the previously used Bohan and Peter criteria developed in 1975.

    Article  Google Scholar 

  15. Zhang X, Yang X, Ji L, Zhang Z. Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR/ACR in Chinese patients. Int J Rheum Dis. 2019. https://doi.org/10.1111/1756-185X.13605.

    Article  CAS  Google Scholar 

  16. Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology Inter. Arthritis Rheum. 2017;69(5):911–23. https://doi.org/10.1002/art.40060.

    Article  CAS  Google Scholar 

  17. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ). Arthritis Care Res. 2011;63(S11):S118–57. https://doi.org/10.1002/acr.20532.

    Article  Google Scholar 

  18. Rider LG, Miller FW, Feldman BM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis Rheum. 1997;40(11):1976–83. https://doi.org/10.1002/art.1780401109.

    Article  CAS  PubMed  Google Scholar 

  19. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4–13. https://doi.org/10.1002/art.23248.

    Article  PubMed  Google Scholar 

  20. McCann LJ, Kirkham JJ, Wedderburn LR, et al. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials. 2015;16(1):268. https://doi.org/10.1186/s13063-015-0784-0.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rosina S, Consolaro A, van Dijkhuizen P, et al. Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology. 2019;58(7):1196–205. https://doi.org/10.1093/rheumatology/key421.

    Article  PubMed  Google Scholar 

  22. Varnier GC, Rosina S, Ferrari C, et al. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res. 2018;70(9):1312–9. https://doi.org/10.1002/acr.23491.

    Article  Google Scholar 

  23. Tiao J, Feng R, Berger EM, et al. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br J Dermatol. 2017;177(4):1086–92. https://doi.org/10.1111/bjd.15596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40. https://doi.org/10.1136/annrheumdis-2016-209247.

    Article  Google Scholar 

  25. Ringold S, Nigrovic PA, Feldman BM, et al. The Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans. Arthritis Rheum. 2018;70(5):669–78. https://doi.org/10.1002/art.40395.

    Article  Google Scholar 

  26. Huber AM, Kim S, Reed AM, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110–6. https://doi.org/10.3899/jrheum.160688

    Article  Google Scholar 

  27. Kim S, Kahn P, Robinson AB, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol. 2017;15(1):1. https://doi.org/10.1186/s12969-016-0134-0.

    Article  Google Scholar 

  28. Hinze CH, Oommen PT, Dressler F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol. 2018;16(1):40. https://doi.org/10.1186/s12969-018-0257-6.

    Article  Google Scholar 

  29. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138. https://doi.org/10.1186/ar4600.

    Article  Google Scholar 

  30. Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019;78(7):988–95. https://doi.org/10.1136/ANNRHEUMDIS-2018-215004.

    Article  Google Scholar 

  31. Miller FW, Chen W, O’Hanlon TP, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 2015;16(7):470–80. https://doi.org/10.1038/gene.2015.28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. •• Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016;75(8):1558–66. https://doi.org/10.1136/ANNRHEUMDIS-2015-208119. This is the largest GWAS of idiopathic inflammatory myopathies to date identifying specific immune genes associated with the clinical subtypes of disease.

    Article  Google Scholar 

  33. Lintner KE, Patwardhan A, Rider LG, et al. Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. Ann Rheum Dis. 2016;75(9):1599–606. https://doi.org/10.1136/annrheumdis-2015-207762.

    Article  CAS  PubMed  Google Scholar 

  34. Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histological features. Arthritis Rheumatol. 2018. https://doi.org/10.1002/art.40800.

    Article  CAS  Google Scholar 

  35. Neely J, Rychkov D, Paranjpe M, Waterfield M, Kim S, Sirota M. Gene Expression Meta‐Analysis Reveals Concordance in Gene Activation, Pathway, and Cell‐Type Enrichment in Dermatomyositis Target Tissues. ACR Open Rheumatol. 2019. https://doi.org/10.1002/acr2.11081.

    Article  Google Scholar 

  36. Gitiaux C, Latroche C, Weiss-Gayet M, et al. Myogenic progenitor cells exhibit type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis. Arthritis Rheum. 2018;70(1):134–45. https://doi.org/10.1002/art.40328.

    Article  CAS  Google Scholar 

  37. Throm AA, Alinger JB, Pingel JT, Daugherty AL, Pachman LM, French AR. Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis. JCI Insight. 2018;3(22). https://doi.org/10.1172/jci.insight.123236.

  38. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology. 2017;56(1):26–36. https://doi.org/10.1093/rheumatology/kew146.

    Article  CAS  PubMed  Google Scholar 

  39. Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-α. Front Immunol. 2018;9:1372. https://doi.org/10.3389/fimmu.2018.01372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Olazagasti JM, Hein M, Crowson CS, et al. Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. J Inflamm. 2015;12(1):29. https://doi.org/10.1186/s12950-015-0075-2.

    Article  CAS  Google Scholar 

  41. Crowson CS, Hein MS, Pendegraft RS, et al. Interferon chemokine score and other cytokine measures track with changes in disease activity in patients with juvenile and adult dermatomyositis. ACR Open Rheumatol. 2019;1(2):83–9. https://doi.org/10.1002/acr2.1011.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Huard C, Gullà SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol. 2017;176(5):1224–30. https://doi.org/10.1111/bjd.15006.

    Article  CAS  PubMed  Google Scholar 

  43. •• Bellutti Enders F, van Wijk F, Scholman R, et al. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheum. 2014;66(8):2281–9. https://doi.org/10.1002/art.38676.. This is the largest study of disease biomarkers for JDM validated in an international cohort.

    Article  CAS  Google Scholar 

  44. Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation. Arthritis Rheum. 2019;71(8):1377–90. https://doi.org/10.1002/art.40881.

    Article  CAS  Google Scholar 

  45. Mamyrova G, Kishi T, Targoff IN, et al. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology. 2018;57(11):1956–63. https://doi.org/10.1093/rheumatology/key190.

    Article  CAS  PubMed  Google Scholar 

  46. Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8. https://doi.org/10.1016/S0140-6736(15)01021-1.

    Article  PubMed  Google Scholar 

  47. Giancane G, Lavarello C, Pistorio A, et al. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatr Rheumatol. 2019;17(1):24. https://doi.org/10.1186/s12969-019-0326-5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA

    Jessica Neely & Susan Kim

Authors
  1. Jessica Neely
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Kim.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Rheumatology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neely, J., Kim, S. Advances Toward Precision Medicine in Juvenile Dermatomyositis. Curr Rheumatol Rep 21, 73 (2019). https://doi.org/10.1007/s11926-019-0873-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-019-0873-2

Keywords

Search

Navigation